HemOnc Today Current Issue

The following articles appeared in the print edition of HemOnc Today.

Table of Contents

• Effort to recruit more minorities for clinical trials becoming ‘national priority’
• ASH announces physician–scientist career development award recipients
• Emicizumab reduces bleeds among children with hemophilia A
• Enrollment of demcizumab trials halted after pancreatic cancer study misses primary endpoint
• Genetic variants may improve bone marrow transplant donor selection, outcomes in ALL
• Letermovir effective as prophylaxis for cytomegalovirus in high-risk hematopoietic cell transplant patients
• Loyola Medicine radiation oncologist receives distinguished service award
• Memorial Sloan Kettering Cancer Center names head of solid tumor oncology
• Mental distress often untreated among adolescent, young adult cancer survivors
• NYU Langone names chief of thoracic surgery
• Penn professor to become American Academy of Orthopaedic Surgeons’ first female president
• Perlmutter Cancer Center names program leader
• Phase 1b trial of HS-110, nivolumab combination meets efficacy endpoint in NSCLC
• Phase 2b study of iobenguane I 131 shows promise for rare neuroendocrine tumors
• Roswell Park Cancer institute appoints vice chair for translational research
• Samuel Waxman Cancer Research Foundation appoints executive director
• Seattle Cancer Care Alliance appoints chief nurse executive
• Study reveals ‘greatly concerning’ lack of financial disclosures among oncologists on Twitter
• Task force recommends against thyroid cancer screening in asymptomatic adults
• University of Louisville selects cancer center director
• ‘We can do better’: ASCO report outlines persistent health care disparities, need for funding
• Zoptarelin doxorubicin fails to extend survival in advanced endometrial cancer
• ‘Special focus’ required to eliminate disparities among millennials with cancer John Sweetenham, MD, FRCP, FACP
• Advocacy group petitions FDA to require cancer risk warnings on acid reflux medications
• FDA accepts supplemental application for Imbruvica for treatment of chronic GVHD
• FDA approves three drugs for advanced urothelial carcinoma
• FDA expands approval of Ibrance for advanced breast cancer
• FDA grants breakthrough therapy designation to CTL019 for DLBCL
• Regulatory updates for NSCLC
• Several agents receive orphan drug designation
• Adjuvant endocrine therapy still misused, underused in patients with breast cancer
• Alternating treatment fails to delay progression of advanced renal cell carcinoma
• Cybersecurity should be a research priority for hospitals
• Fondaparinux cost-effective for heparin-induced thrombocytopenia
• Genomic alterations similar between black and white patients with lung cancer
• Hormonal maintenance therapy prolongs PFS for serous carcinoma of ovary, peritoneum
• Induction chemotherapy extends failure-free survival in locoregionally advanced nasopharyngeal carcinoma
• Lenalidomide, bortezomib, dexamethasone with HSCT prolongs PFS in myeloma
• Longer telomeres associated with increased cancer risk
• Myeloablative conditioning prolongs RFS for AML, myelodysplastic syndrome
• Noncancer-specific mortality increases with age in patients with stage I NSCLC
• Single 8-Gy radiotherapy dose reduces pain from bone metastases
• Smoking increases risk for death, disease progression in CML
• Vemurafenib produces response in brain metastatic melanoma
• Watch-and-wait helps patients avoid radical surgery for rectal cancer
• Younger age linked to poorer survival from second cancers
• Active surveillance ‘reasonable’ for younger men with low-risk prostate cancer
• Adjuvant capecitabine therapy extends survival in biliary tract cancer
• BRCA mutations may increase risk for prostate cancer
• Contralateral breast cancer uncommon among women with ductal carcinoma in situ
• EINSTEIN-CHOICE: Recurrent VTE lower with rivaroxaban vs. aspirin, without rise in bleeding
• Flu vaccine may cause immune-related adverse events with checkpoint inhibitors
• Gefitinib delays recurrence in some patients with lung cancer
• Men may require more frequent lung cancer screenings
• Treatments other than surgery may influence risk for breast cancer–related lymphedema
• Trimodality therapy may reduce locoregional recurrence in inflammatory breast cancer
• Biosimilar interchangeability: What it means for clinicians Edward C. Li, PharmD, MPH, BCOP
• Are subset analyses an effective way to overcome the lack of data from minorities in clinical trials?